Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

NCT06160752 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
Solid Tumor
Metastatic Cholangiocarcinoma

Interventions

DRUG: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles
DRUG: Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles

Sponsor

Tyra Biosciences, Inc